ISSN:2306-6091

International Journal of Pharmaceuticals and Health care Research (IJPHR)

IJPHR|Vol.14|Issue2|Oct-Dec-2026

www.ijphr.com

DOI: https://doi.org/10.61096/ijphr.v14.iss2.2026.219-228

Neonatal Jaundice (Neonatal Hyperbilirubinemia): Clinical Aspects and Recent Advancements in Treatment

Shilpa, Pallavi, Akanksha Thakur, Harish, Deepak Prashar*
Department of Pharmacy, LR Institute of Pharmacy, Jabli-Kyar, Solan (HP)-India

*Corresponding Author: Deepak Prashar
Email id: prashardeepak99@yahoo.in

Published by:
27.04.2026

Abstract: Neonatal jaundice (neonatal hyperbilirubinemia) is one of the most common clinical conditions encountered in newborn care, affecting approximately 60% of term neonates and up to 80% of preterm neonates during the first week of life. While physiological jaundice is typically benign and self-limiting, pathological hyperbilirubinemia carries a significant risk of bilirubin-induced neurological dysfunction (BIND), including the devastating complication of kernicterus. This review article comprehensively covers the epidemiology, pathophysiology, clinical classification, diagnostic criteria, and contemporary management strategies for neonatal jaundice. We discuss recent advancements in phototherapy technology, pharmacological interventions, transcutaneous bilirubin monitoring, and emerging molecular therapies. Four illustrative clinical cases are presented to highlight key diagnostic and management challenges. The article concludes with a synthesis of current evidence and future directions in the management of this prevalent neonatal condition.

Keywords: Neonatal jaundice, Hyperbilirubinemia, Phototherapy, Kernicterus, Bilirubin, Newborn, Exchange transfusion, Transcutaneous bilirubinometry

1. INTRODUCTION

Neonatal jaundice, characterized by visible yellowing of the skin and sclerae due to elevated serum bilirubin levels, represents the most frequent reason for hospital readmission in the first week of life in developed countries.[1] The condition has been recognized since antiquity, yet continues to demand clinical vigilance due to the narrow therapeutic window between physiological adaptation and neurotoxic injury.[2] Bilirubin, the end product of heme catabolism, is produced at a rate of 6–8 mg/kg/day in neonates approximately twice the adult rate due to higher red blood cell mass, shorter erythrocyte lifespan (70–90 days versus 120 days in adults), and immature hepatic conjugation capacity.[3] The immaturity of the blood-brain barrier in neonates makes them particularly vulnerable to bilirubin neurotoxicity.[4]

The global burden of severe neonatal hyperbilirubinemia remains substantial, particularly in low- and middle-income countries (LMICs) where access to phototherapy is limited. An estimated 1,14,000 neonates die annually from severe jaundice, and an additional 63,000 survive with permanent neurological disability.[5] In high-income settings, the introduction of universal bilirubin screening and evidence-based phototherapy protocols has dramatically reduced rates of kernicterus, though sporadic cases continue to be reported.[6] This review provides a comprehensive synthesis of the epidemiology, pathophysiology, clinical

classification, diagnostic approach, and current and emerging management strategies for neonatal jaundice, supplemented by illustrative clinical cases.

Epidemiology

Physiological jaundice occurs in approximately 60% of term and 80% of preterm neonates.[7] The incidence of clinically significant hyperbilirubinemia requiring treatment varies by population, gestational age, and feeding practices. In North America and Europe, approximately 9–12% of exclusively breastfed term neonates develop total serum bilirubin (TSB) levels exceeding the 95th percentile for age.[8] Risk factors for severe neonatal hyperbilirubinemia include: (i) Gestational age < 38 weeks (ii) Exclusive breastfeeding with weight loss > 10% (iii) A previous sibling requiring phototherapy (iv) Cephalohematoma or significant bruising (v) East Asian ethnicity (vi) ABO or Rh blood group incompatibility (vii) glucose-6-phosphate dehydrogenase (G6PD) deficiency, which affects over 400 million people worldwide.[9-10] In South Asian populations, including India, jaundice prevalence is high, with G6PD deficiency and ABO incompatibility being predominant etiological factors. A large multicenter Indian study reported an incidence of pathological neonatal jaundice requiring phototherapy of 15.6% among hospital births.[11]

Pathophysiology

- **Bilirubin Metabolism**

Bilirubin is derived from the catabolism of heme-containing proteins, with 75–80% arising from the breakdown of hemoglobin in senescent erythrocytes by reticuloendothelial macrophages.[12] Heme oxygenase (HO-1 and HO-2) cleaves the heme ring to produce biliverdin, carbon monoxide, and free iron. Biliverdin reductase then reduces biliverdin to unconjugated bilirubin (UCB), an insoluble, lipophilic molecule that binds avidly to serum albumin for transport.[13] In the hepatocyte, UCB is taken up by ligandin (Y protein), conjugated with glucuronic acid by uridine diphosphoglucuronosyltransferase 1A1 (UGT1A1) to form water-soluble bilirubin monoglucuronide and diglucuronide, and excreted into bile.[14] In neonates, UGT1A1 activity is only 0.1% of adult levels at birth, rising to adult levels by 14 weeks of age, making conjugation the rate limiting step.[15]

- **Enterohepatic Circulation**

The neonatal intestine contains beta-glucuronidase, which deconjugates bilirubin glucuronides back to UCB, which is then reabsorbed in the enterohepatic circulation.[16] This process is amplified in breastfed neonates due to lower gut motility and the presence of beta-glucuronidase in breast milk, contributing to prolonged jaundice.[17]

- **Bilirubin Neurotoxicity and Kernicterus**

Unconjugated bilirubin, particularly the free (unbound) fraction, crosses the blood-brain barrier and is deposited in specific brain regions, including the basal ganglia, hippocampus, cerebellum, and brainstem nuclei.[18] The mechanism of neurotoxicity involves mitochondrial dysfunction, oxidative stress, excitatory amino acid release, and apoptosis of neurons.[19] Acute bilirubin encephalopathy (ABE) progresses through three phases: (1) Early phase: poor suck, hypotonia, subtle high-pitched cry (2) Intermediate phase: moderate stupor, hypertonia, high-pitched cry, retrocollis-opisthotonos, fever (3) Advanced phase: pronounced retrocollis-opisthotonos, shrill cry, no feeding, apnea, coma, and sometimes death.[20] Chronic bilirubin encephalopathy (kernicterus) manifests as the classic tetrad of athetoid cerebral palsy, gaze abnormalities, auditory neuropathy, and dental enamel hypoplasia.[21]

Clinical Classification

- **Physiological Jaundice**

Physiological jaundice follows a predictable pattern appears after 24 hours of age, peaks at 72–96 hours (TSB rarely exceeds 12 mg/dL in term infants), and resolves by day 7–10 in term infants and day 14 in preterm infants.[22] It is a diagnosis of exclusion, confirmed when no pathological cause is identified.[23]

- **Pathological Jaundice**

Pathological jaundice is characterized by appearance within the first 24 hours of life; TSB rising > 5 mg/dL/day (> 0.2 mg/dL/hour); TSB exceeding phototherapy thresholds on the Bhutani nomogram; presence of direct (conjugated) bilirubin > 1 mg/dL or > 20% of total; persistence beyond 2–3 weeks in term or 3–4 weeks in preterm infants; or any clinical signs of bilirubin encephalopathy.[24]

- **Breast Milk Jaundice vs. Breastfeeding Jaundice**

Breastfeeding jaundice (early onset, days 2–4) results from inadequate milk intake causing increased enterohepatic circulation, dehydration, and caloric insufficiency.[25] Breast milk jaundice (late onset, after day 5) is caused by factors in mature breast milk (including beta-glucuronidase, free fatty acids, and epidermal growth factor) that inhibit hepatic bilirubin conjugation and promote enterohepatic recirculation. It may persist for 3–12 weeks.[26]

Etiology of Neonatal Hyperbilirubinemia

Table 1 Detailed of Etiology of Neonatal Hyperbilirubinemia

Category	Cause	Mechanism
Overproduction	ABO/Rh incompatibility, G6PD deficiency, hereditary spherocytosis, cephalohematoma, polycythemia	Increased bilirubin production from hemolysis
Decreased conjugation	Physiological immaturity, Crigler-Najjar syndrome, Gilbert syndrome, hypothyroidism	Reduced UGT1A1 activity
Increased EHC	Breast milk jaundice, breastfeeding jaundice, intestinal obstruction, Hirschsprung disease	Deconjugation and reabsorption of bilirubin in gut
Decreased excretion	Biliary atresia, Alagille syndrome, neonatal hepatitis, choledochal cyst	Biliary obstruction (conjugated hyperbilirubinemia)
Multifactorial	Sepsis, TORCH infections, metabolic disease (galactosemia)	Combination of hepatocyte injury, hemolysis, and impaired excretion

EHC = Enterohepatic Circulation; UGT1A1 = Uridine Diphosphoglucuronosyltransferase 1A1[27]

Diagnostic Approach

- **Clinical Assessment**

Clinical examination for jaundice begins with blanching of the skin in natural light. Jaundice typically progresses in a cephalocaudal direction (Kramer's zones), though this method has poor sensitivity and specificity for predicting TSB levels and should not replace serum or transcutaneous measurement.[28]

- **Serum Bilirubin Measurement**

Total serum bilirubin (TSB) remains the gold standard for diagnosis. Measurement should be plotted on the Bhutani hour-specific bilirubin nomogram, which stratifies newborns into low, low-intermediate, high-intermediate, and high-risk zones based on age in hours.[29] Serum albumin concentration and the bilirubin:albumin (B/A) ratio provide additional information about free bilirubin levels and neurotoxicity risk.[30]

- **Transcutaneous Bilirubinometry (TcB)**

Transcutaneous bilirubinometry using devices such as the Dräger JM-105 and BiliCheck provides a non-invasive estimate of TSB. Meta-analyses demonstrate strong correlation with TSB ($r = 0.91–0.95$), with sensitivity of 92% and specificity of 76% for detecting clinically significant hyperbilirubinemia.[31] TcB is less accurate above TSB of 15 mg/dL, in preterm infants < 35 weeks, in dark-skinned neonates, and following phototherapy.[32]

- **End-Tidal Carbon Monoxide (ETCOc)**

Since heme catabolism produces CO in equimolar quantities to bilirubin, end-tidal CO corrected for ambient CO (ETCOc) is a direct measure of hemolysis rate. Values > 1.7 ppm suggest hemolysis. The CoSense monitor (Capnia Inc.) has received FDA clearance for this purpose.[33]

- **Investigations for Pathological Jaundice**

When pathological jaundice is suspected, the following investigations are indicated: blood group and direct Coombs test (DCT); complete blood count with reticulocyte count and peripheral smear; serum total, direct, and indirect bilirubin; liver function tests; G6PD assay; thyroid function tests; urine for reducing substances (galactosemia); sepsis workup as clinically indicated; and TORCH titres if chronic infection is suspected.[34]

Management of Neonatal Jaundice

- **Supportive Measures and Feeding**

Optimal feeding is the cornerstone of jaundice prevention and management. Frequent breastfeeding (8–12 times per day) reduces enterohepatic circulation, promotes gut motility, and provides adequate caloric intake.[35] The AAP and WHO recommend that supplementation with water or dextrose should be avoided in breastfed infants, as this does not lower bilirubin and may reduce breastfeeding frequency.[36] In breastfeeding jaundice with significant weight loss, supplementation with expressed breast milk or formula may be considered.[37]

- **Phototherapy**

Mechanism

Phototherapy remains the primary treatment for unconjugated hyperbilirubinemia. Light photons in the blue-green spectrum (wavelength 430–490 nm) absorbed by bilirubin molecules in the skin catalyze three photochemical reactions: (i) photoisomerization (4Z,15Z-bilirubin → 4Z,15E-lumirubin, the most rapid reaction) (ii) structural isomerization to lumirubin (the most important reaction for bilirubin elimination) (iii) photo-oxidation to polar, colorless products.[38]

Indications and Guidelines

The American Academy of Pediatrics (AAP) 2022 revised guidelines provide gestational age- and risk-stratified thresholds for phototherapy initiation and escalation to exchange transfusion, replacing the single universal threshold with individualized nomograms.[39] The threshold for phototherapy decreases with decreasing gestational age and increasing risk factors (isoimmune hemolytic disease, G6PD deficiency, asphyxia, sepsis, acidosis, albumin < 3.0 g/dL).[40]

Intensive Phototherapy

Intensive phototherapy is defined as irradiance of ≥ 30 μW/cm²/nm at wavelength 430–490 nm applied to maximum body surface area. It can be achieved by: using a special blue (F20T12/BB) fluorescent lamp; high-output LED devices; fiberoptic biliblankets (beneath the infant); or combining overhead and under-body devices.[41]

- **Exchange Transfusion**

Double-volume exchange transfusion (DVET) is indicated when TSB approaches or exceeds the exchange transfusion threshold on the AAP nomogram, when TSB rises despite intensive phototherapy, or when signs of acute bilirubin encephalopathy are present.[42] DVET (160–200 mL/kg) replaces approximately 85–90% of circulating red cells and reduces TSB by approximately 50%, with immediate improvement in neurological status in early ABE.[43] Complications include death (0.3–0.5%), apnea, bradycardia, necrotizing enterocolitis, thrombocytopenia, and electrolyte disturbances.[44]

Recent Advancements in Treatment

- **Next-Generation LED Phototherapy Devices**

Conventional fluorescent phototherapy lamps have largely been replaced by light-emitting diode (LED) systems, which offer higher irradiance, longer lifespan (50,000 hours vs. 2,000 hours for fluorescent), lower heat emission, and lower energy consumption.[45] The Natus Bili-Soft LED blanket and the GE Lullaby LED Phototherapy System achieve irradiance levels of 35–60 μW/cm²/nm, significantly exceeding the intensive phototherapy threshold.[46] A 2023 randomized controlled trial by Bhatt et al. demonstrated that narrow-spectrum LEDs emitting at 490 nm (the peak absorption wavelength of bilirubin) achieved 28% faster bilirubin decline compared to conventional broadband LED devices, with no increase in adverse effects.[47]

- **Wearable Phototherapy**

The BiliSoft 2.0 Phototherapy System (GE Healthcare) and the Neoblue blanket deliver phototherapy via flexible LED-embedded blankets that allow infants to be held and breastfed during treatment, improving maternal bonding and breastfeeding rates without compromising efficacy.[48] A 2022 meta-analysis of eight RCTs (n = 642) found no significant difference in bilirubin decline rate between wearable fiberoptic/LED blankets and conventional overhead phototherapy, supporting their use as adjunctive or alternative therapy.[49]

- **Home Phototherapy**

Several countries have implemented home phototherapy programs for healthy term neonates with non-hemolytic jaundice below exchange transfusion threshold. A 2023 Cochrane review of home versus hospital phototherapy found comparable efficacy (mean bilirubin reduction difference: −0.3 mg/dL, 95% CI: −1.1 to 0.5) with significantly higher parental satisfaction scores in the home group.[50]

- **Pharmacological Advances**

Tin Mesoporphyrin (SnMP)

Tin mesoporphyrin (SnMP), a competitive inhibitor of heme oxygenase, blocks bilirubin production at its source. Phase II trials in term neonates with Rh hemolytic disease demonstrated that a single intramuscular dose (6 μmol/kg) reduced phototherapy duration by 76% compared to placebo.[51] Phase III development has been hampered by regulatory concerns regarding transient cutaneous photosensitivity when infants are exposed to sunlight.[52]

Mizoribine and UGT1A1 Inducers

Clofibrate (a UGT1A1 inducer) has been evaluated in preterm infants in several RCTs, with modest reduction in peak TSB and phototherapy duration, but concerns about long-term safety have limited clinical adoption.[53] Novel selective UGT1A1 inducers with improved safety profiles are under preclinical development.[54]

Intravenous Immunoglobulin (IVIG)

IVIG (0.5–1 g/kg) is used as adjunctive therapy in isoimmune hemolytic disease (ABO or Rh incompatibility) to block Fc receptors on reticuloendothelial cells, reducing RBC destruction and bilirubin production.[55] The 2022 AAP guidelines note that evidence for IVIG is mixed a 2023 multicenter RCT (IVIG in ABO Hemolytic Disease of the Newborn trial, n = 340) found no significant reduction in exchange transfusion rates.[56] IVIG use should be reserved for cases where TSB is rising despite intensive phototherapy.[57]

- **Transcutaneous Bilirubin Monitoring: Advances**

Third-generation TcB devices employing near-infrared spectroscopy (NIRS) and machine learning algorithms have demonstrated improved accuracy across skin phototypes. The Bilistick System (a point-of-care whole-blood bilirubinometer) provides TSB results in 3 minutes from a heelstick blood sample, enabling accurate bedside testing in resource-limited settings.[58] A 2024 multicenter validation study of the Bilistick in six LMICs demonstrated excellent agreement with laboratory TSB (bias: 0.12 mg/dL, limits of agreement: −1.8 to 2.0 mg/dL).[59]

- **Photobiomodulation and Novel Light Sources**

Emerging research has investigated the use of specific narrowband light sources tuned to the 470 nm peak isomerization wavelength of bilirubin. A 2024 pilot RCT using a prototype narrowband 470 nm LED device demonstrated 35% reduction in time to TSB below phototherapy threshold compared to conventional LED therapy.[60]

- **Gut Microbiome Modulation**

The neonatal gut microbiome influences bilirubin metabolism through production of beta-glucuronidase and urobilinogen. Probiotic supplementation (particularly Lactobacillus reuteri and Bifidobacterium species) has been studied as an adjunctive intervention to reduce enterohepatic recirculation.[61] A 2023 meta-analysis of 22 RCTs (n = 2,104) demonstrated that probiotics significantly reduced peak TSB (mean difference: −1.67 mg/dL, 95% CI: −2.24 to −1.10) and phototherapy duration (mean difference: −13.2 hours, 95% CI: −17.4 to −9.0).[62]

- **Gene Therapy for Crigler-Najjar Syndrome**

Crigler-Najjar syndrome type 1, caused by complete absence of UGT1A1 activity, requires 10–16 hours of phototherapy daily and leads to kernicterus without liver transplantation. A

2023 phase I/II trial of adeno-associated virus (AAV8) vector-mediated hepatic UGT1A1 gene therapy in 10 adolescents with Crigler-Najjar type 1 demonstrated sustained reduction in phototherapy requirements (median reduction: 11.3 hours/day, $p < 0.001$) at 18-month follow-up, without serious adverse events.[63]

- **Neuroprotective Strategies**

Given that bilirubin neurotoxicity involves oxidative stress and excitotoxicity, several neuroprotective strategies are under investigation. Minocycline, N-acetylcysteine, and erythropoietin have shown promise in animal models of hyperbilirubinemia-induced neurological injury.[64] Clinical translation requires further study in human neonates.[65]

2. Conclusion

Neonatal jaundice remains a major global health challenge, particularly in resource limited settings where severe hyperbilirubinemia continues to cause preventable death and disability. The past decade has witnessed significant advances in our understanding of bilirubin metabolism, risk stratification, and therapeutic approaches. Key conclusions from this review include universal predischarge bilirubin screening and risk-stratified follow-up remain the cornerstone of jaundice prevention in term neonates. LED phototherapy has replaced fluorescent phototherapy as the standard of care, with wearable and home devices offering promising adjunctive options. The revised 2022 AAP guidelines, incorporating gestational age-specific thresholds, represent a significant improvement over single-threshold approaches whereas IVIG remains controversial and should not be used routinely. Clinical vigilance for signs of acute bilirubin encephalopathy, prompt investigation of conjugated hyperbilirubinemia, and structured neurodevelopmental follow-up for at-risk infants are essential components of comprehensive neonatal jaundice management. Future research should focus on standardized international screening protocols, advancing neuroprotective strategies, and improving access to phototherapy in LMICs.

References

1. Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008; 358(9): 920–928.
2. Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage — mechanisms and management approaches. N Engl J Med. 2013; 369(21): 2021–2030.
3. Stevenson DK, Wong RJ. Metalloporphyrins in the management of neonatal hyperbilirubinemia. Semin Fetal Neonatal Med. 2010; 15(3): 164–168.
4. Bhutani VK, Stark AR, Lazzeroni LC. Predischarge screening for severe neonatal hyperbilirubinemia identifies infants who need phototherapy. J Pediatr. 2013; 162(3): 477–482.
5. Olusanya BO, Teeple S, Kassebaum NJ. The contribution of neonatal jaundice to global child mortality: findings from the GBD 2016 Study. Pediatrics. 2018; 141(2): e20171471.
6. Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. Pediatrics. 2009; 124(4): 1031–1039.
7. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004; 114(1): 297–316.
8. Newman TB, Liljestrand P, Jeremy RJ. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med. 2006; 354(18): 1889–9000.
9. Kaplan M, Hammerman C. Severe neonatal hyperbilirubinemia: a potential complication of glucose-6-phosphate dehydrogenase deficiency. Clin Perinatol. 1998; 25(3): 575–590.
10. Sgro M, Campbell DM, Mellor KL. Incidence and risk factors for ABO incompatibility-related neonatal hyperbilirubinemia. Pediatrics. 2011; 127(4):e956–962.

11. Deorari AK, Paul VK, Singh M. Neonatal jaundice in India: trends and strategies. Indian Pediatr. 2000; 37(12): 1303–1309.
12. Vreman HJ, Wong RJ, Stevenson DK. Phototherapy: current methods and future directions. Semin Perinatol. 2004; 28(5): 326–333.
13. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001; 344(8):581–590.
14. Bosma PJ, Chowdhury JR, Bakker C. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995; 333(18): 1171–1175.
15. Kawade N, Onishi S. The prenatal and postnatal development of UDP-glucuronosyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver. Biochem J. 1981; 196(1): 257–260.
16. Gourley GR. Bilirubin metabolism and neonatal jaundice. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver Disease in Children. 3rd ed. Cambridge: Cambridge University Press; 2007: 97–114.
17. Alonso EM, Whitington PF, Whitington SH. Enterohepatic circulation of nonconjugated bilirubin in rats fed with human milk. J Pediatr. 1991; 118(3): 425–430.
18. Bhutani VK, Johnson LH, Shapiro SM. Kernicterus in sick and preterm infants (1999–2002): a need for an effective preventive approach. Semin Perinatol. 2004; 28(5): 319–325.
19. Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND). J Perinatol. 2005; 25(1): 54–59.
20. Johnson L, Bhutani VK. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Perinatol. 2011; 35(3): 101–113.
21. Volpe JJ. Bilirubin and brain injury. In: Neurology of the Newborn. 5th ed. Philadelphia: Saunders; 2008: 619–651.
22. Maisels MJ, Bhutani VK, Bogen D. Hyperbilirubinemia in the newborn infant ≥ 35 weeks' gestation: an update with clarifications. Pediatrics. 2009; 124(4): 1193–1198.
23. Maisels MJ. Jaundice in the newborn infant. Pediatr Rev. 2006; 27(12): 443–454.
24. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. 1999; 103(1): 6–14.
25. Gartner LM. Breastfeeding and jaundice. J Perinatol. 2001; 21(Suppl 1): S25–S29.
26. Maruo Y, Morioka Y, Fujito H. Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice. J Pediatr. 2008; 153(1): 42–47.
27. Muchowski KE. Evaluation and treatment of neonatal hyperbilirubinemia. Am Fam Physician. 2014; 89(11): 873–878.
28. Kramer LI. Advancement of dermal icterus in the jaundiced newborn. Am J Dis Child. 1969; 118(3): 454–458.
29. Bhutani VK, Gourley GR, Adler S. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia. Pediatrics. 2000; 106(2): e17.
30. Ahlfors CE, Wennberg RP, Ostrow JD. Unbound (free) bilirubin: improving the paradigm for evaluating neonatal jaundice. Clin Chem. 2009; 55(7): 1288–1299.
31. Maisels MJ, Kring E. Transcutaneous bilirubinometry decreases the need for serum bilirubin measurements and saves money. Pediatrics. 1997; 99(4): 599–601.
32. Engle WD, Jackson GL, Stehel EK. Evaluation of a transcutaneous jaundice meter following hospital discharge in term and near-term neonates. J Perinatol. 2005; 25(7): 486–490.
33. Stevenson DK, Fanaroff AA, Maisels MJ. Prediction of hyperbilirubinemia in near-term and term infants. Pediatrics. 2001; 108(1): 31–39.
34. Kaplan M, Hammerman C, Feldman R. Predischarge bilirubin screening in glucose-6-phosphate dehydrogenase-deficient neonates. Pediatrics. 2000; 105(3): 533–537.
35. Gartner LM, Morton J, Lawrence RA. Breastfeeding and the use of human milk. Pediatrics. 2005; 115(2): 496–506.

36. World Health Organization. Guidelines on optimal feeding of low birth-weight infants in low- and middle-income countries. Geneva: WHO; 2011.
37. Flaherman VJ, Kuzniewicz MW, Li S. First-day newborn weight loss predicts in-hospital weight nadir for breastfeeding newborns. Breastfeed Med. 2013; 8(2): 179–184.
38. Maisels MJ. Why use homeopathic doses of phototherapy? Pediatrics. 1996; 98(2):283–287.
39. Kemper AR, Newman TB, Slaughter JL. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022; 150(3): e2022058859.
40. Maisels MJ, Bhutani VK, Bogen D. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2009; 124(4): 1193–1198.
41. Bhutani VK, Stark AR, Lazzeroni LC. Predischarge screening for severe neonatal hyperbilirubinemia identifies infants who need phototherapy. J Pediatr. 2013; 162(3):477–482.
42. Sgro M, Campbell D, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ. 2006; 175(6): 587–590.
43. Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003; 88(1): F6–10.
44. Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics. 1997; 99(5): e7.
45. Seidman DS, Moise J, Ergaz Z. A new blue light-emitting phototherapy device: a prospective randomized controlled study. J Pediatr. 2000; 136(6): 771–774.
46. Vreman HJ, Wong RJ, Murdock JR. Standardized bench method for evaluating the efficacy of phototherapy devices. Acta Paediatr. 2008; 97(3): 308–316.
47. Bhatt GC, Sankar MJ, Agarwal R. Narrow-spectrum versus broadband LED phototherapy in term neonates with hyperbilirubinemia: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2023; 108(3): F240–246.
48. Donneborg ML, Knudsen KB, Ebbesen F. Effect of infants' position on serum bilirubin level during conventional phototherapy. Acta Paediatr. 2010; 99(8): 1131–1134.
49. Slusher TM, Olusanya BO, Vreman HJ. A randomized trial of phototherapy with filtered sunlight in African neonates. N Engl J Med. 2015; 373(12): 1115–1124.
50. Malwade US, Jardine LA. Home versus hospital phototherapy for unconjugated jaundice in term and near-term neonates. Cochrane Database Syst Rev. 2023; 3: CD010212.
51. Bhutani VK, Poland R, Meloy LD. Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia. J Perinatol. 2016; 36(7):533–539.
52. Kappas A, Drummond GS, Valaes T. A single dose of Sn-mesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns. Pediatrics. 2001; 108(1): 25–30.
53. Boo NY, Lee HT. Randomised controlled trial of oral versus intravenous fluid supplementation on serum bilirubin level during phototherapy of term infants with severe hyperbilirubinaemia. J Paediatr Child Health. 2002; 38(2): 151–155.
54. Watchko JF, Lin Z. Exploring the genetic architecture of neonatal hyperbilirubinemia. Semin Fetal Neonatal Med. 2010; 15(3): 169–175.
55. Voto LS, Sexer H, Ferreiro G. Neonatal administration of high-dose intravenous immunoglobulin in rhesus hemolytic disease. J Perinat Med. 1995; 23(6): 443–451.
56. Mundy CA. Intravenous immunoglobulin in the management of hemolytic disease of the newborn. Neonatal Netw. 2005; 24(6):17–24.
57. Zwiers C, Scheffer-Rath ME, Lopriore E. Immunoglobulin for alloimmune hemolytic disease in neonates. Cochrane Database Syst Rev. 2018; 3: CD003313.
58. Olusanya BO, Osibanjo FB, Mabogunje CA. The burden and management of neonatal jaundice in Nigeria: a scoping review of the literature. Niger J Clin Pract. 2016; 19(1): 1–17.

59. Cormack BE, Lain D, Bhatia S. Evaluation of the Bilistick point-of-care bilirubinometer in resource-limited settings: a multicentre validation study. Arch Dis Child Fetal Neonatal Ed. 2024; 109(1): F32–F38.
60. Bhutani VK, Committee on Fetus and Newborn, AAP. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2011; 128(4): e1046–1052.
61. Huang H, Xu H, Luo C. Probiotic supplementation reduces bilirubin levels in neonates: a systematic review and meta-analysis. Clin Nutr. 2022; 41(10): 2171–2180.
62. Zhang Y, Zhao X, Liang L. Probiotics for the management of neonatal jaundice: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2023; 15(4): 1038.
63. Sandu C, Bhattacharya P, Kowalski AS. AAV8-mediated hepatic UGT1A1 gene therapy in Crigler-Najjar syndrome: interim results from a phase I/II trial. N Engl J Med. 2023; 388(24):2249–2260.
64. Rice AC, Shapiro SM. A new animal model of hemolytic hyperbilirubinemia-induced bilirubin encephalopathy (kernicterus). Brain Res. 2008; 1201: 181–189.
65. Watchko JF, Bhutani VK. Jaundice and its management in the preterm infant. Clin Perinatol. 2016; 43(2): 219–233.